ALL 67.01 Allstate Corp $ALL Hit a 52 week high of 67.19

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
ALL 67.01 Allstate Corp $ALL Hit a 52 week high of 67.19 Closing the day 09:44 at 67.01 -0.36 -0.53% With a day low of 66.88 and a total volume of 136,218.

ALL Recent Posts: http://investorshangout.com/Allstate-Corporation-ALL-50077/

ALL Allstate Corp Recent Headline News

Allstate to Present at Goldman Sachs Financial Services Conference
PR Newswire - 11 mins ago
The Allstate Corporation (NYSE: ALL), the nation's largest publicly held personal lines insurer, announced that Thomas J. Wilson, its chairman, president and chief executive officer, will present at the Goldman Sachs Financial Services Conference at 10:50 a.m. Eastern Time on Tuesday, December 9. The conference is being held at the Conrad New York Hotel in New York.
ALL: 67.08 (-0.29)

One in Four Employed Americans Required to Work over the Holidays, Finds Allstate/National Journal Heartland Monitor Poll
PR Newswire - 2 hrs 11 mins ago
Approximately one quarter of the American workforce will be required to work on Thanksgiving, Christmas Day or New Year's Day. Despite this, American workers express not only satisfaction in their own work, but also pride in the role their employers play in communities. These are among the key findings of the 21st Allstate/National Journal Heartland Monitor Poll, which surveyed Americans' attitudes toward their jobs and, employers and the encroachment of the workplace into other facets of life.
ALL: 67.08 (-0.29)

3 Stocks Advancing The Financial Sector
at The Street - Wed Nov 19, 11:16AM CST
TheStreet highlights 3 stocks pushing the financial sector higher today.
MAC: 76.32 (-0.26), ALL: 67.08 (-0.29), TCO: 78.16 (-0.39)

Allstate declares dividend of USD0.28 per share for quarter
M2 - Wed Nov 19, 3:31AM CST
The Allstate Corporation (NYSE:ALL), a personal lines insurer, declared on Tuesday that it will pay a quarterly cash dividend of USD0.28 per share on its common stock.
ALL: 67.08 (-0.29)

The Allstate declares $0.28 dividend
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 11:00AM CST

ALL: 67.08 (-0.29)

Allstate Announces Dividends
PR Newswire - Tue Nov 18, 10:43AM CST
The Allstate Corporation (NYSE: ALL) today announced a quarterly dividend of 28 cents on each outstanding share of the corporation's common stock, payable in cash on January 2, 2015, to stockholders of record at the close of business on November 28, 2014.
ALL: 67.08 (-0.29)

Earnings Look Back: Allstate Is Up 5.7% Since Reporting Quarterly Results 2 Weeks Ago (ALL)
Comtex SmarTrend(R) - Mon Nov 17, 10:26AM CST
19 days ago, on October 29th, 2014, Allstate (NYSE:ALL) reported its earnings. Analysts, on average, expected earnings of $1.33 per share on sales of $8.6 billion. The company actually reported EPS of $1.39 on sales of $8.9 billion, beating EPS estimates by $0.05 and beating revenue estimates by $293.3 million. Shares of Allstate have climbed from $62.98 to $66.58, representing a gain of 5.7% since the company reported earnings 19 days ago.
ALL: 67.08 (-0.29)

Allstate (ALL) Stock Declines Today on Analyst Downgrade
at The Street - Mon Nov 17, 8:58AM CST
Allstate (ALL) stock is lower this morning after the company had its rating cut to 'market perform' from 'outperform' at Keefe, Bruyette & Woods.
ALL: 67.08 (-0.29)

Earnings Briefing and Analysis - Allstate
PR Newswire - Mon Nov 17, 8:00AM CST
Investor-Edge.com has issued free earnings analysis on The Allstate Corp. (NYSE: ALL). On October 29, 2014, the company reported its financial results for Q3 FY14 (period ended September 30, 2014). Click on www.investor-edge.com/FreeReports to read our free earnings review on The Allstate Corp. (Allstate). During Q3 FY14, the company's diluted EPS surged 163.6% from Q3 FY13, and its consolidated revenues grew 5.6% from the previous year quarter. Our free coverage report can be accessed at:
ALL: 67.08 (-0.29)

Downgrade Alert for Allstate (ALL)
Comtex SmarTrend(R) - Mon Nov 17, 7:59AM CST
Allstate (NYSE:ALL) was downgraded from Outperform to Market Perform at Keefe Bruyette today. The stock closed yesterday at $66.58 on volume of 1.5 million shares, below average daily volume of 2.5 million. The Allstate Corporation, through its subsidiaries, provides property-liability insurance, as well as other types of insurance in the United States and Canada. The Company primarily sells private passenger automobile and homeowners insurance through independent and specialized brokers. Allstate also sells life insurance, annuity, and group pension products through agents.
ALL: 67.08 (-0.29)

Allstate Hits 52-Week High; Core Growth Initiatives Promising - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 11:50AM CST
Shares of The Allstate Corp. (ALL) have scaled new 52-week high of $67.32, indicating a compelling long-term story.
AFSI: 51.15 (-0.15), ACGL: 57.30 (+0.07), CNO: 17.39 (-0.03), ALL: 67.08 (-0.29)

NFL's Peyton Manning Wants to Make Buying Insurance Sexy
at The Street - Fri Nov 14, 8:45AM CST
Insurance companies have turned en masse to professional athletes in an attempt to spice up a bland product.
PGR: 27.06 (-0.05), HAS: 56.07 (-0.06), NKE: 96.77 (-0.18), S: 4.77 (+0.06), MET: 54.43 (-0.39), DTV: 87.19 (-0.03), BRK.B: 145.27 (-0.38), BRK.A: 217,880.76 (-664.16), ALL: 67.08 (-0.29), MA: 84.06 (-0.22), PEP: 98.18 (-0.23)

New Allstate/National Journal Heartland Monitor Poll Finds Narrow Majority of Americans See Work/Life Balance as Attainable
PR Newswire - Fri Nov 14, 7:00AM CST
Despite concerns about the direction of the country and the likelihood of compromise in Washington following the mid-term election, a majority of the American public believes that most people can still find a way to balance the demands of work, family and contributions to community. These are among the key findings of the 21st Allstate/National Journal Heartland Monitor Poll, which explores what Americans believe is necessary to balance their obligations at work, at home and in their neighborhoods and what they think could help them do better.
ALL: 67.08 (-0.29)

Free Allstate App Helps Homeowners Inventory Their Belongings
PR Newswire - Thu Nov 13, 4:37PM CST
According to a recent "Protect It Or Lose It" survey from Allstate, nearly all homeowners (90 percent) are concerned about protecting their homes, yet haven't valued their possessions in years - let alone documented what they have. From furniture to jewelry to even bedding and bath towels, it's important to have a record of your possessions should something happen to your home. To help homeowners get a handle on the task, Allstate is launching a new version of Digital Locker®, a free mobile app which makes taking a home inventory a click away.
ALL: 67.08 (-0.29)

Wet Winter Forecast Ahead for Southern States: Know How Your City Drivers Stack Up In Rain and Snow
PR Newswire - Tue Nov 11, 4:05AM CST
The National Oceanic and Atmospheric Administration (NOAA) predicts this winter (2014-2015) will have higher than average precipitation in the Southern United States. Allstate Insurance Company reminds customers and consumers to know how cities' drivers perform when wetter conditions are factored into their America's Best Drivers Report® ranking, and recommends preparing for the winter roads ahead.
ALL: 67.08 (-0.29)

Insurance ETFs in Focus on String of Q3 Earnings and Revenue Beats - ETF News And Commentary
Sweta Killa - ZACKS - Mon Nov 10, 1:00PM CST
Earnings from the insurance industry have been encouraging with most of the firms beating our estimates on both the revenue and the earnings front.
IAK: 48.90 (-0.12), PRU: 83.72 (-0.43), MET: 54.43 (-0.39), CB: 102.17 (-0.01), AIG: 54.14 (+0.12), KIE: 65.64 (-0.03), AFL: 58.79 (-0.27), ALL: 67.08 (-0.29), TRV: 103.08 (+0.05), KBWI: 68.43 (+0.13)

Earnings Flashback: Since Reporting Quarterly Results 1 Week Ago Allstate Is Up 5.2% (ALL)
Comtex SmarTrend(R) - Mon Nov 10, 9:12AM CST
A week ago on October 29th, 2014 Allstate (NYSE:ALL) reported earnings and analysts, on average, expected earnings of $1.33 on sales of $8.6 billion. The company actually reported EPS of $1.39 on sales of $8.9 billion, beating EPS estimates by $0.05 and beating revenue estimates by $293.3 million. Since the company's report, shares of Allstate have risen from $62.98 to $66.25, representing a gain of 5.2% in the past 12 days.
ALL: 67.08 (-0.29)

Allstate Hails Best Reinsurance Coverage Ever, Helped By Cat Bonds
Steve Evans - Seeking Alpha - Sat Nov 08, 10:29AM CST
U.S. primary insurer Allstate (NYSE: ALL ) has hailed its current reinsurance program as the best coverage it’s ever had, as the availability of lower-cost ILS and alternative reinsurance capital, plus recent catastrophe bond issuances, help it...
TPRE: 14.60 (+0.01), ALL: 67.08 (-0.29), GLRE: 31.74 (+0.12)

After Yesterday's Rally of 1.31% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Nov 05, 4:55PM CST
Allstate (NYSE:ALL) traded in a range yesterday that spanned from a low of $65.14 to a high of $65.75. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $65.15 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALL: 67.08 (-0.29)

Allstate Corporation (ALL) Stock Research Links

ALL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Driven Tech Lands on 2026 CRN AI Innovators List

Updated Category News Views 4

New Milestone for Driven Tech in AI Innovation If there's one thing that's becoming crystal clear in the tech world, it's this: AI isn't just a flashy add-on anymore. Companies are diving deep into AI waters, transforming their business strategies from the ground up. Driven Tech, Inc., is doing just that, and their efforts haven't gone unnoticed—they’ve made it onto...

Continue Reading
Clarivate Taps Global Appetite for AI Research Tools

Updated Category News Views 8

A Growing Global Thirst for AI-Enhanced Research It looks like the folks at Clarivate have struck a chord. Their Web of Science Research Intelligence platform is garnering attention across the globe, embraced by more than 100 institutions spanning 25 countries. When you craft something that taps into a core need, well, people will jump on it—and that's exactly what's...

Continue Reading
PKGD Group's Agave Spirits Surge 56% in 2026 Growth'

Updated Category News Views 1

PKGD Group's Impressive Growth Story Sometimes you read a report and it genuinely knocks the wind out of you—not because it’s unusual, but because it’s rare to see such robust numbers in a market that ain't exactly all sunshine and rainbows. PKGD Group, the brain behind some damn fine agave spirits, decided to take no prisoners this year, reporting a jaw-dropping...

Continue Reading
ELEGOO's M1 Ultra: Bridging Gap in 3D Scanning Tech

Updated Category News Views 3

A Leap in 3D Scanning: Say Hello to M1 Ultra ELEGOO isn't just fiddling with a toy here—this Shenzhen-based juggernaut is rolling out the M1 Ultra on October 29, 2026, and it's causing quite a stir. While the stock market doesn't see immediate tremors from every shiny new gadget, there’s something to say when a company that pulled over $300 million in sales last year...

Continue Reading
Rznomics Advances with EU Orphan Status for RZ-001

Updated Category News Views 3

RZ-001's European Success: A New Frontier Look, when a biopharmaceutical firm's RNA-editing therapy snags an Orphan Medicinal Product Designation from the European Commission, it's not just some clipboard milestone—it's a heavy-hitter move. That's exactly what Rznomics, the South Korean gene therapy player, pulled off with RZ-001. Now, we aren't just seeing paperwork...

Continue Reading
Durabook R12 Tablet: A Rugged Revolution for AI Tasks

Updated Category News Views 7

Edge AI Gets a Rugged Boost with Durabook's R12 In a world teeming with tech gadgets that crumble at the first sign of a challenge, Durabook's R12 Rugged Tablet makes a solid entrance. This ain't your everyday pretty gadget. Think of it as the big, burly bodyguard of tablets, ready to box through harsh environments without dropping a pixel. What’s stirring the pot this...

Continue Reading
When Families Should Consider Life Insurance Plans

Updated Category News Views 0

Let’s talk about why life insurance isn’t just for those walking around with gray hair. K.D. the Insurance Queen from Centennial, Colorado, dishes out the clearest advice on when and why families ought to have it in their arsenal. A New Mindset on Life Insurance Some folks out there think life insurance is something you ponder in your twilight years. But here’s the...

Continue Reading
Hims & Hers Faces Class Action: Investor Implications

Updated Category News Views 6

Serious Scrutiny for Hims & Hers There's trouble in paradise, folks. Hims & Hers Health, Inc. (NYSE: HIMS) just landed in hot water, and it's not the soothing kind. We're talking about allegations of privacy violations and deceptive practices that have sent ripples—or more like waves—across the investor pond. If you're holding shares, you've probably felt the jolt...

Continue Reading
UMC and AP Memory Boost Power with New AI Chips

Updated Category News Views 4

Breaking Ground in Data Center Power Every so often, the tech industry gets a jolt of innovation that turns heads—not just for what it can do today, but for what it promises tomorrow. This time, it's United Microelectronics Corporation (UMC) and AP Memory shaking things up with their collaboration aimed at redefining power delivery for AI and high-performance computing...

Continue Reading
AuraQuantic Leads SPARK Matrix™ in 2026 IPO Ranking

Updated Category News Views 2

Not Just Another Day in Tech When tech outfits make headlines, it's often because of a shiny new gadget or some jarring security breach. Today, it's AuraQuantic getting their well-deserved spotlight, having snagged the leader's spot in the SPARK Matrix™ for Intelligent Process Orchestration (IPO). You might be wondering what makes this accolade worth attention in a...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Atlassian's Recent Options Activity Surge

Updated Category News Views 163

Analyzing Atlassian's Options Activity Recently, significant activity has been noted in the options market for Atlassian (NASDAQ: TEAM), suggesting fluctuating sentiment among investors. With several key trades occurring, it is vital to understand the underlying forces driving these changes. Insights from Options Trading An examination of options history indicates that a...

Continue Reading
Oncolytics Biotech's Strategic Move to Lead Cancer Innovation

Updated Category News Views 176

Oncolytics Biotech's Strategic Move to Lead Cancer Innovation In a time where the global oncology drug market is projected to exceed an astounding $900 billion, interest in cancer-focused biotechnology companies has surged significantly. Analysts highlight the increasing demand for innovative diagnostics and advanced immunotherapies driving this growth. Yet, as these...

Continue Reading
Transformations in Admirals Group AS Leadership and Governance

Updated Category News Views 170

Changes in Leadership at Admirals Group AS Admirals Group AS recently held a significant general meeting where key changes to its management and supervisory boards were decided. Effective from a stated future date, Anton Tikhomirov and Fedor Ragin have been appointed to the supervisory board for a term of five years. This shift marks an exciting new chapter in the...

Continue Reading
Athens Stock Market Reaches New Heights with Gains

Updated Category News Views 175

Athens Stock Market Performance Overview The latest updates reveal that Greece's stock market has closed on a positive note, showcasing notable increases across various sectors. The Athens General Composite Index has gained traction, finishing higher as key market sectors, particularly Construction, Travel, and Banking, experienced substantial growth. Sectorwise...

Continue Reading
Johnson & Johnson's Tremfya Shows Promising Results for Crohn's Disease

Updated Category News Views 227

Introduction to Tremfya and Crohn's Disease Tremfya, a medication developed by Johnson & Johnson, has gained notable attention for its role in treating Crohn's disease. Recently, new results from its Phase 3 GRAVITI study have sparked interest in its potential expanded usage, showing promising outcomes for patients. Exciting Results from the GRAVITI Study The GRAVITI...

Continue Reading